Peter Hawkins

457 total citations
13 papers, 193 citations indexed

About

Peter Hawkins is a scholar working on Physiology, Hematology and Genetics. According to data from OpenAlex, Peter Hawkins has authored 13 papers receiving a total of 193 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 5 papers in Hematology and 5 papers in Genetics. Recurrent topics in Peter Hawkins's work include Erythrocyte Function and Pathophysiology (8 papers), Blood disorders and treatments (5 papers) and Hemoglobinopathies and Related Disorders (4 papers). Peter Hawkins is often cited by papers focused on Erythrocyte Function and Pathophysiology (8 papers), Blood disorders and treatments (5 papers) and Hemoglobinopathies and Related Disorders (4 papers). Peter Hawkins collaborates with scholars based in United States, United Kingdom and Netherlands. Peter Hawkins's co-authors include Miguel Holmgren, Dora M. Berman, Sarah Gheuens, Eduard J. van Beers, Héctor Rasgado-Flores, Hanny Al‐Samkari, Wilma Barcellini, D.B. Shennan, Erin Zagadailov and Satheesh Chonat and has published in prestigious journals such as New England Journal of Medicine, Blood and American Journal of Physiology-Cell Physiology.

In The Last Decade

Peter Hawkins

12 papers receiving 190 citations

Peers

Countries citing papers authored by Peter Hawkins

Since Specialization

Citations

This map shows the geographic impact of Peter Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hawkins more than expected).

Fields of papers citing papers by Peter Hawkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hawkins. The network helps show where Peter Hawkins may publish in the future.

Co-authorship network of co-authors of Peter Hawkins

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hawkins. A scholar is included among the top collaborators of Peter Hawkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hawkins. Peter Hawkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy Subjects 2024 ·Clinical Pharmacology in Drug Development ·Varsha Iyer, Karen A. Sullivan, (unknown), Peter Hawkins	1
2	Deep vein thrombosis as thrombotic sequelae of vaccine-induced thrombotic thrombocytopenia 2023 ·Oxford Medical Case Reports ·(unknown), (unknown), David A. Morrow, (unknown), Peter Hawkins, (unknown)	0
3	Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial 2022 ·The Lancet Haematology ·Andreas Glenthøj, Eduard J. van Beers, Hanny Al‐Samkari, Vip Viprakasit, Kevin H.M. Kuo, Frederic Galactéros, Satheesh Chonat, John B. Porter, Erin Zagadailov, (unknown), (unknown), Peter Hawkins, Sarah Gheuens, Vanessa Beynon, Wilma Barcellini	28
4	A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease 2022 ·Blood ·Julia Xu, Anna Conrey, Ingrid Frey, (unknown), Laurel A. Menapace, Laxminath Tumburu, (unknown), (unknown), Quan Li, (unknown), Emily B. Dunkelberger, Varsha Iyer, (unknown), Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William A. Eaton, Swee Lay Thein	47
5	Mitapivat versus Placebo for Pyruvate Kinase Deficiency 2022 ·New England Journal of Medicine ·Hanny Al‐Samkari, Frédéric Galactéros, Andreas Glenthøj, Jennifer Rothman, Oliver Andrés, Rachael F. Grace, (unknown), D. Mark Layton, Koichi Onodera, Madeleine Verhovsek, Wilma Barcellini, Satheesh Chonat, (unknown), Erin Zagadailov, (unknown), Peter Hawkins, Vanessa Beynon, Sarah Gheuens, Eduard J. van Beers	47
6	P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY 2022 ·HemaSphere ·Wilma Barcellini, Rachael F. Grace, Hanny Al‐Samkari, Andreas Glenthøj, Jennifer Rothman, (unknown), D. Mark Layton, Oliver Andrés, (unknown), Peter Hawkins, (unknown), Feng Tai, (unknown), (unknown), Eduard J. van Beers	2
7	Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study 2021 ·Blood ·Julia Xu, Anna Conrey, Ingrid Frey, (unknown), Laurel A. Menapace, Laxminath Tumburu, (unknown), Quan Li, (unknown), Varsha Iyer, (unknown), Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William A. Eaton, Swee Lay Thein	8
8	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency 2020 ·Blood ·Hanny Al‐Samkari, Rachael F. Grace, (unknown), Oliver Andrés, Wilma Barcellini, Frederic Galactéros, Kevin H.M. Kuo, D. Mark Layton, Marta Morado, Vip Viprakasit, Yan Dong, Feng Tai, Peter Hawkins, Sarah Gheuens, Chris Bowden, John B. Porter, Eduard J. van Beers	4
9	Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease 2020 ·Blood ·Julia Xu, Anna Conrey, Ingrid Frey, James Nichols, Laurel A. Menapace, Laxminath Tumburu, (unknown), Quan Li, Emily B. Dunkelberger, Eric R. Henry, Troy Cellmer, Varsha Iyer, (unknown), Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William A. Eaton, Swee Lay Thein	7
10	Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study 2019 ·Blood ·Rachael F. Grace, D. Mark Layton, Frederic Galactéros, Wilma Barcellini, Eduard J. van Beers, Hassan M. Yaish, Yaddanapudi Ravindranath, Kevin H.M. Kuo, Sujit Sheth, Janet L. Kwiatkowski, Lei Hua, Peter Hawkins, (unknown), Bertil Glader	3
11	Protein‐protein interactions between two‐component system transmitter and receiver domains of *Myxococcus xanthus* 2008 ·PROTEOMICS ·David E. Whitworth, Andrew Millard, David A. Hodgson, Peter Hawkins	10
12	Volume-sensitive taurine efflux from mammary tissue is not obliged to utilize volume-activated anion channels 1996 ·Bioscience Reports ·D.B. Shennan, Matthew J. Cliff, Peter Hawkins	12
13	External Ca effect on water permeability, regulatory volume decrease, and extracellular space in barnacle muscle cells 1993 ·American Journal of Physiology-Cell Physiology ·Dora M. Berman, (unknown), Miguel Holmgren, Peter Hawkins, Héctor Rasgado-Flores	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact